CTMX Q4 2018 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-57.6% YoY

Gross Profit

$11M100.0% margin

Operating Income

-$26M-225.0% margin

Net Income

-$32M-281.0% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

-8.3%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$457M

Total Liabilities

$326M

Stockholders' Equity

$131M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$27M	-57.6%
Gross Profit	$11M	$27M	-57.6%
Operating Income	-$26M	-$1M	-1969.8%
Net Income	-$32M	$621,000	-5290.5%